RBC keeps USD 110.00 target for Zimmer Biomet stock
RBC Capital has maintained its Buy rating and USD 110.00 price target for Zimmer Biomet stock (ZBH) following strong second-quarter 2026 earnings. The company reported a 4.80% increase in revenue to USD 2.18 billion and raised its full-year organic constant currency revenue growth guidance. Zimmer Biomet's stock was trading at EUR 78.95, up 0.62% from the prior close, with its next earnings report expected on November 4, 2026.
Intuitive Surgical Inc. Research & Ratings | ISRG
This article provides a detailed research and ratings overview for Intuitive Surgical Inc. (ISRG), including analyst ratings, price targets, stock grader information, company financials, and earnings estimates. It shows a consensus "Buy" rating with an average price target of $479.86 and details upcoming earnings reports.
CH147843075 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the CH147843075 bond issued by Zimmer Biomet Holdings, Inc. It outlines key facts such as the issuer, maturity date, face value, and minimum denomination. The bond has a 1.56% annual coupon, and the article details its coupon payment schedule and redemption information.
Zimmer Biomet Holdings Inc. (ZIM.SG) Q2 FY2026 earnings call transcript
Zimmer Biomet Holdings Inc. reported strong Q2 FY2026 results, with net sales of $2.177 billion, exceeding expectations with 4.8% reported growth and 4% organic constant currency growth. The company raised its full-year organic constant currency revenue guidance to 2.25%-3.25% and adjusted EPS to $8.47-$8.59, driven by successful U.S. sales channel transformation, new product momentum, and healthy markets. Key growth drivers included strong hip sales (5.1% constant currency growth), particularly in the U.S. with new technologies like Z1, HAMMR, and OrthoGrid, and significant growth in Technology and Data, Bone Cement, and Surgical segments (21.5%), bolstered by record capital sales of ROSA with OptimiZe and ROSA Shoulder.
Intuitive Surgical Inc. Stock Grades | ISRG
This article provides detailed stock information for Intuitive Surgical Inc. (ISRG), including its current stock grade, analyst ratings, key financial metrics, and company overview. It highlights an average price target of $479.86 from 35 ratings and notes the company's P/E Ratio (TTM) of 44.92. The company specializes in robotic-assisted surgical solutions.
RBC Capital Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)
RBC Capital analyst Kendall Au reiterated a Buy rating on Zimmer Biomet Holdings (ZBH) with a price target of $110.00. This affirmation follows the company's Q2 earnings report, which showed increased revenue and net profit compared to the previous year. Zimmer Biomet Holdings currently holds a Moderate Buy consensus among analysts, with an average price target of $106.07.
Zimmer Biomet stock trades at USD 88.29 as RBC keeps target
Zimmer Biomet's stock is trading at USD 88.29, with RBC Capital maintaining a "Buy" rating and a USD 110 price target. The company reported Q2 revenue of USD 2.18 billion, a 4.8% increase year-over-year, and a 30.0% increase in net profit. Despite strong profit growth, the stock remains 17.4% below its 52-week high, creating a valuation debate for investors.
ZBH6004607 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Zimmer Biomet Holdings, Inc. bond ZBH6004607, highlighting its key facts, coupon payments, and redemption information. The bond has a 4.7% coupon rate, matures on February 19, 2027, and has a face value of $1,000. It also outlines the company's business activities and geographical segments.
A director acquires 306 cash-settled stock units at Zimmer Biomet (ZBH), payable in five annual installments.
Robert Hagemann, a director at Zimmer Biomet Holdings, Inc. (ZBH), acquired 306.0660 phantom stock units on September 30, 2026, under the Deferred Compensation Plan for Non-Employee Directors. His balance now totals 33,660.8400 units, including those from dividend reinvestment. These units will be cash-settled in five annual installments, starting within 60 days after his director service concludes.
A director at Zimmer Biomet (ZBH) acquired 417.363 units payable in cash.
Michael J. Farrell, a director at Zimmer Biomet Holdings, Inc. (ZBH), acquired 417.363 phantom stock units on September 30, 2026, under the company's Deferred Compensation Plan for Non-Employee Directors. These units are to be settled in cash in a lump sum within sixty days after he ceases serving as a director. Following this transaction, Farrell's total holding of phantom stock units reached 20,073.731.
A director acquires 174 deferred stock units at Zimmer Biomet (ZBH), payable in shares after service ends.
Zimmer Biomet Holdings, Inc. director Devdatt Kurdikar acquired 173.9010 phantom stock units on September 30, 2026. These units, accrued under the Deferred Compensation Plan for Non-Employee Directors, will be settled in common stock on a 1-for-1 basis within 60 days after his service as a director ends. The acquisition brings his direct balance to 3,171.3590 units, including those accrued via dividend reinvestment.
Director Kolli acquires 173.901 deferred stock units at Zimmer Biomet (ZBH).
Zimmer Biomet Holdings, Inc. director Sreelakshmi Kolli acquired 173.9010 Phantom Stock Units on September 30, 2026, under the company's Deferred Compensation Plan for Non-Employee Directors. After this transaction, her reported holdings totaled 7,033.7570 Phantom Stock Units, which includes units accrued through dividend reinvestment. These units are scheduled to be settled in company common stock within sixty days of Kolli's departure from her director service.
Director acquires 375.626 cash-settled stock units at Zimmer Biomet (ZBH).
Zimmer Biomet Holdings, Inc. director Maria Teresa Hilado acquired 375.626 phantom stock units on September 30, 2026, under the Deferred Compensation Plan for Non-Employee Directors. After this transaction, her direct balance increased to 13,392.107 units. These phantom units will be settled in cash through ten annual installments, beginning within 60 days after she ceases her director service.
Director Arthur J. Higgins acquires 306.066 cash-settled units at Zimmer Biomet (ZBH).
Arthur J. Higgins, a director at Zimmer Biomet Holdings, Inc. (ZBH), acquired 306.066 cash-settled Phantom Stock Units on September 30, 2026, under the Deferred Compensation Plan for Non-Employee Directors. These units will be settled in ten annual cash installments after his service as a director ends. Following this transaction, his total balance of Phantom Stock Units stands at 38,077.496.
ADSEW - ADS-TEC ENERGY PLC Warrant stock news, filings & ratings
This article provides an overview of ADS-TEC ENERGY PLC Warrant (ADSEW), a B2B technology company specializing in intelligent battery buffered energy systems. It details the company's products, stock performance, recent SEC filings, and relevant news, highlighting its market position within the Industrial Specialties industry.
Zimmer Biomet stock after-hours at EUR 78.77
Zimmer Biomet's stock traded after-hours at EUR 78.77 according to Lang & Schwarz. This follows leadership changes announced earlier in September, including new appointments for President, Americas, and President, Recon, S.E.T., CMFT, Neuro and Biosurgery, effective October 1, 2026. The company also reiterated its full-year 2026 financial outlook.
Carlsmed names new CFO
Carlsmed has appointed Richard Heppenstall, formerly CFO of ZimVie, as its new Chief Financial Officer, replacing Leo Greenstein. Despite Greenstein's departure, analysts expect no significant change in Carlsmed's strategy. The company reaffirmed its full-year sales guidance of $74 million to $78 million, anticipating 50% growth over 2025 sales, driven by surgeon onboarding and new product launches like the Aprevo platform.
Zimmer Biomet Holdings, Inc. $ZBH Holdings Lifted by Envestnet Asset Management Inc.
Envestnet Asset Management Inc. increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4% in Q2, bringing their total to 308,571 shares valued at $26.6 million. The company reported strong Q2 earnings, exceeding expectations with $2.07 EPS and $2.18 billion in revenue, and declared a quarterly dividend of $0.24 per share. Despite cautious analyst sentiment with a consensus "Hold" rating, institutional investors collectively own 88.89% of the stock.
Zimmer Biomet stock holds at USD 91.62 as BMO keeps target
Zimmer Biomet stock closed at USD 91.62, with BMO Capital maintaining a USD 96.00 price target after evaluating the company's new iodine-coated hip implant in Japan. The company's Q2 2026 adjusted EPS of USD 2.07 beat consensus, and revenue reached USD 2.18 billion. Management raised its fiscal 2026 EPS and revenue growth guidance, reflecting optimism despite manufacturing constraints and the stock remaining below its yearly high.
Zimmer Biomet stock closes at USD 91.04 on September 25, 2026
Zimmer Biomet's stock closed at USD 91.04 on September 25, 2026. The company also announced several leadership changes effective October 1, including new presidents for different regions and business units, while reiterating its full-year 2026 financial outlook.
What Changed for Zimmer Biomet (NYSE:ZBH) After Dividend Update?
Zimmer Biomet (NYSE:ZBH), a medical technology company specializing in orthopedic implants and surgical products, recently declared a quarterly dividend. The article highlights the company's core business in orthopedic products, its integration of robotics and digital technologies, and its recent financial performance which included higher revenue and earnings per share. Zimmer Biomet's position within the healthcare sector and its continuous product expansion through acquisitions are also discussed.
BMO reiterates Zimmer Biomet stock rating on Japan hip implant opportunity
BMO Capital has reiterated a Market Perform rating and a $96.00 price target for Zimmer Biomet (NYSE:ZBH) shares, citing the opportunity presented by the company's iodine-coated hip implant launch in Japan. The firm estimates the Japan hip market to be around $500 million, with a significant conversion opportunity for Zimmer Biomet despite near-term manufacturing capacity constraints. The company recently reported strong Q2 2026 financial results, exceeding expectations, and raised its full-year guidance, leading Needham to also reiterate a Hold rating.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shareholders to Get $0.24 Quarterly Dividend
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has declared a quarterly dividend of $0.24 per share, payable on October 30th to shareholders of record on September 30th. This represents an annualized dividend of $0.96 and a dividend yield of 1.1%, with a healthy payout ratio of 11.5%. The company also reported strong quarterly earnings, beating analyst expectations with $2.07 EPS and $2.18 billion in revenue.
Edwards Lifesciences Corporation (NYSE:EW) Stock Has Average Target Price of $100.27
Edwards Lifesciences (NYSE:EW) has received a "Moderate Buy" rating from analysts, with an average target price of $100.27, suggesting an upside from its current share price of $86.39. The company recently surpassed quarterly earnings and revenue expectations and has significant institutional ownership. Despite some insider selling, analysts maintain a positive outlook, with several firms reiterating "buy" or "outperform" ratings and increasing price targets.
Zimmer Biomet (ZBH): Buy, Sell, or Hold Post Q2 Earnings?
Zimmer Biomet (ZBH) has shown underwhelming performance with a 4.4% return over the last six months, falling short of the S&P 500's 16.9% gain. The article highlights disappointing long-term revenue growth, barely growing EPS, and inefficient growth initiatives as reasons to pass on the stock. It suggests looking for better opportunities, despite the current fair valuation.
Zimmer Biomet stock trades at USD 91.57, up 2.10 percent in New York trading
Zimmer Biomet stock traded at USD 91.57, up 2.10 percent in New York trading, outperforming the SPY's 0.46 percent gain. The stock opened at USD 89.53 and reached a session high of USD 91.84, with trading volume at 474,121 shares. Analyst estimates from Zacks support the move, with 10 analysts revising fiscal 2026 earnings estimates higher and the company also announced a quarterly dividend of USD 0.24 per share with a record date of September 30, 2026.
Zimmer Biomet stock falls 1.31 percent despite higher 2026 guidance
Zimmer Biomet's stock fell 1.31% despite the company raising its fiscal 2026 guidance for revenue growth and adjusted EPS. The medical device company reported second-quarter 2026 adjusted EPS of $2.07 and revenue of $2.18 billion, both beating analyst estimates. Although operational expectations improved, the stock trades below its yearly peak, and analysts maintain a consensus "Hold" rating with an average price target above the current trading price.
Zimmer Biomet Holdings, Inc. $ZBH Holdings Lifted by State Street Corp
State Street Corp increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.6% during the second quarter, now owning 4.65% of the company's shares. Zimmer Biomet reported strong quarterly results, exceeding revenue and adjusted EPS expectations, and declared a quarterly dividend of $0.24 per share. Despite these positive financial indicators, analysts maintain a cautious "Hold" rating on the stock with an average price target of $103.
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?
This article compares Intuitive Surgical (ISRG) and Stryker (SYK), two major players in the MedTech sector, evaluating which is the better investment. While Stryker offers diversified MedTech exposure and recovering capital-product momentum, Intuitive Surgical presents a more focused growth story with stronger operational momentum and a growing digital ecosystem. The article concludes that Intuitive Surgical is currently the more attractive bet due to its robotics leadership, recurring revenues, and expanding clinical applications, despite trading at a higher premium.
Minimally Invasive Robotic Surgical System Market Global Report 2026: Benchmark Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet Now
The global minimally invasive robotic surgical system market is projected to reach $18.15 billion by 2030, growing from $8.9 billion in 2025 due to increased precision, patient outcomes, and adoption in outpatient facilities. Key growth drivers include improved reimbursement, precision medicine, and demand for minimally invasive procedures. Product innovation and strategic acquisitions by major players like Intuitive Surgical, Johnson & Johnson, and Medtronic are strengthening the market, with North America currently the largest regional market and Asia-Pacific expected to be the fastest-growing.
Zimmer Biomet stock slips as shares close at USD 94.32
Zimmer Biomet Holdings, Inc. stock closed at USD 94.32 on September 22, 2026, marking a 1.1 percent decline from the prior session. This price is USD 12.56 below its 52-week high, although it remains closer to its annual high than its low. The company reported a revenue of USD 8.23 billion for fiscal year 2025, showing a 7.2 percent increase from 2024.
Nykredit A S Takes $3.22 Million Position in Zimmer Biomet Holdings, Inc. $ZBH
Nykredit A/S recently acquired 37,377 shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH), establishing a new position valued at approximately $3.22 million. Institutional investors collectively own 88.89% of the company, and analysts have a "Hold" rating with a consensus price target of $103.00. Zimmer Biomet reported strong quarterly earnings, exceeding expectations with $2.07 adjusted EPS and $2.18 billion in revenue, and declared a quarterly dividend of $0.24 per share.
Zimmer Biomet stock slips 1.1 percent ahead of the open
Zimmer Biomet stock declined 1.1 percent, closing at USD 94.32 on September 22, 2026, on the New York Stock Exchange. The stock traded between USD 93.71 and USD 96.17, with 3,945,673 shares exchanged. This close was significantly below its 52-week high, and the broader market showed mixed performance with technology gains.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Recommendation of "Hold" by Brokerages
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has received a consensus "Hold" rating from 22 brokerages, with an average 12-month price target of $103.00. The company recently exceeded quarterly expectations, reporting $2.07 in adjusted EPS and $2.18 billion in revenue, and has declared a quarterly dividend of $0.24 per share. Insider transactions show recent sales by Kevin R. Thornal and Chad F. Phipps, while institutional investors own a significant 88.89% of the stock.
Ambulatory Surgery Centers Are Becoming ISRG's New Growth Engine
Intuitive Surgical (ISRG) is targeting Ambulatory Surgery Centers (ASCs) as a key growth area for its robotic-surgery platforms, particularly with its refurbished XiR models. This strategy aims to broaden its customer base by offering lower-cost entry points into robotic surgery. Other companies like Stryker (SYK) and Zimmer Biomet (ZBH) are also focusing on the ASC market with their respective technologies and portfolios.
Zimmer Biomet Holdings, Inc. rStock (RZBH) Price Prediction for 2026 to 2031
Bybit AI provides price predictions for Zimmer Biomet Holdings, Inc. rStock (RZBH) from 2026 to 2031, based on user consensus ratings and historical patterns. The article highlights potential long-term growth for RZBH, estimating a value of approximately $0.00 by 2030, while cautioning about crypto market volatility. It also includes an FAQ section addressing common questions about RZBH's future price.
ETFs Investing in Zimmer Biomet Holdings, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold Zimmer Biomet Holdings, Inc. (1ZBH) stocks. It provides details for each ETF, including market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information aims to help investors find accessible and diversified opportunities with lower risk.
Zimmer Biomet to Showcase Complete Shoulder Solution Designed to Support Surgeon Flexibility
Zimmer Biomet announced it will showcase its complete shoulder solutions, including the updated ROSA Shoulder System and Signature Vision, at the 16th International Congress of Shoulder and Elbow Surgery (ICSES 2026). These technologies aim to provide surgeons with flexibility and precision for personalized shoulder care, addressing various clinical considerations. The offerings include robotic-assisted surgery, mixed reality navigation, pre-operative planning software, and a range of implant systems for both anatomic and reverse arthroplasty.
2,177,724 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by Bank of America Corp DE
Bank of America Corp DE has acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH), purchasing over 2.1 million shares valued at approximately $187.48 million in the second quarter. This move makes Bank of America Corp DE one of several institutional investors increasing their stakes in the medical equipment provider. Despite insider stock sales and a recent dip in share price, analysts maintain a "Hold" rating for Zimmer Biomet, with the company also announcing a quarterly dividend.
GE HealthCare Technologies (GEHC) Stock Forecast and Price Target 2026
GE HealthCare Technologies (GEHC) currently holds a "Hold" consensus rating from 21 Wall Street analysts, with an average 12-month price target of $77.73, representing a potential upside of 19.93% from its current price of $64.81. Analysts issued 11 hold ratings and 10 buy ratings. The article also details bull and bear cases, including the company's strategic push into AI-enabled solutions and potential acquisition talks, versus legal investigations, increased short interest, and competitive pressures.
Zimmer Biomet Executive Thornal Kevin R Disposes of 5,691 Shares at $92.95 Each (NYSE: ZBH)
Thornal Kevin R, Group President of Global Business at Zimmer Biomet, has sold all 5,691 of his shares in the company at a price of $92.95 each. This transaction resulted in a complete divestment of his holdings, leaving him with a zero share balance. The sale, classified as an open-market transaction, occurred on September 11, 2026.
Bank of America Corp DE Takes $605.40 Million Position in Edwards Lifesciences Corporation $EW
Bank of America Corp DE has acquired a significant new stake in Edwards Lifesciences Corporation (NYSE:EW), purchasing over 6.69 million shares valued at approximately $605.40 million during the second quarter. This move makes Bank of America Corp DE a 1.16% owner of Edwards Lifesciences. Other institutional investors have also adjusted their holdings, while several analysts have issued "buy" or "outperform" ratings for the stock with price targets around $100-$110.
Zimmer Biomet Executive Kevin R. Thornal Sells 5,691 Shares at $92.95 Each
Kevin R. Thornal, Group President of Global Business at Zimmer Biomet Holdings, Inc., sold 5,691 shares of the company's common stock on September 11, 2026, at a price of $92.95 per share. This transaction was disclosed in a Form 4 filing on September 15, 2026, and after the sale, Thornal holds zero directly owned shares of Zimmer Biomet. The filing confirmed no derivative security transactions for Thornal.
Zimmer Biomet (NYSE:ZBH) Insider Sells $528,978.45 in Stock
Zimmer Biomet (NYSE:ZBH) insider Kevin Thornal sold 5,691 shares of the company's stock for approximately $528,978 on September 11th. This transaction comes as the company reported strong financial performance, exceeding quarterly earnings and revenue expectations. Despite the insider sale, analysts maintain a "Hold" rating for ZBH with an average price target of $104.42, and the company recently declared a quarterly dividend.
Apollo rumoured to be eyeing $20bn takeover of J&J’s orthopaedics business
Apollo Global Management is reportedly in non-binding talks to acquire Johnson & Johnson's orthopaedics unit, DePuy Synthes, for nearly $20 billion. This potential deal comes as J&J plans to spin out DePuy Synthes to focus on high-growth markets, despite the unit generating $9.3 billion in sales last year. Analysts suggest the $20 billion valuation might be on the lower end, hinting at potential distress or risk perceived by J&J.
Apollo rumoured to be eyeing $20bn takeover of J&J’s orthopaedics business
Apollo Global Management is reportedly in non-binding talks to acquire Johnson & Johnson's orthopaedics unit, DePuy Synthes, for nearly $20 billion. This potential deal comes as J&J plans to spin out DePuy Synthes to sharpen its focus on high-growth markets. While other private equity firms are interested, regulatory hurdles make it unlikely that major competitors like Stryker or Zimmer would bid due to potential market dominance issues.
How Zimmer Biomet’s New Americas and Robotics Leadership Structure At Zimmer Biomet Holdings (ZBH) Has Changed Its Investment Story
Zimmer Biomet Holdings (ZBH) has announced a significant leadership restructuring, promoting key internal figures to lead Americas, Recon, and Americas – Robotics, Technology and Data segments, while a Group President departed. This move emphasizes regional execution and technology-driven growth, particularly in robotics and AI-driven surgery platforms. Investors should consider how this new structure, coupled with competitive pressures in robotics, will influence the company's ability to achieve its projected revenue and earnings targets.
Zimmer proposes to cut 580 jobs in Switzerland
Zimmer Biomet has proposed cutting up to 580 jobs at its manufacturing facility in Winterthur, Switzerland, as part of an ongoing strategy to optimize its manufacturing network. The company is currently engaged in a collective consultation process with the works council to explore alternatives and minimize job losses. This move follows previous reductions in its Winterthur presence and coincides with the development of a new manufacturing plant in Costa Rica aimed at increasing supply chain resilience and accessing lower-cost geographies.
J&J looking to offload orthopedics unit in $20B deal to Apollo: Bloomberg
Johnson & Johnson is reportedly close to selling its DePuy Synthes orthopedics business to private equity firm Apollo Equity Management for approximately $20 billion. This potential deal aligns with J&J's previously announced plan to separate its orthopedics unit, following a trend of biopharma companies divesting non-core assets to focus on core medicine innovation. The orthopedics unit generated $9.3 billion in sales in 2025 and produces implants for joint replacements and surgical instruments.
Corient Private Wealth LP Acquires 227,947 Shares of Edwards Lifesciences Corporation $EW
Corient Private Wealth LP significantly increased its stake in Edwards Lifesciences Corporation by over 1,000%, acquiring an additional 227,947 shares. This move is part of a broader trend of institutional investors, including California State Teachers Retirement System and BlackRock Inc., increasing their holdings in the medical research company. The article also details recent analyst ratings, insider trading activity, and positive news regarding CMS expanding TAVR coverage, which is expected to boost demand for Edwards Lifesciences' products.
